Navigation Links
Statement From Volcano Corporation on Latest St. Jude Lawsuit
Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) today issued the following statement:

Earlier this year, the Massachusetts Superior Court rejected claims by LightLab Imaging, a wholly-owned subsidiary of St. Jude Medical, that Volcano Corporation and its wholly-owned subsidiary, Axsun Technologies, misappropriated LightLab's confidential information in connection for use in the development of Volcano's Optical Coherence Tomography (OCT) System.  Now LightLab is bringing similar claims in a new lawsuit filed May 24, 2011 in a Delaware court, in which LightLab alleges that Axsun is somehow wrongfully participating in Volcano's development of alternative OCT light sources, including initiatives underway with third parties.  

Volcano denies these unfounded allegations.  Volcano firmly believes that this latest lawsuit has no merit, and looks forward to the opportunity to proving so in court.  

About Volcano Corporation

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive.  Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements.  Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, product development milestones, outcome of ongoing litigation, the impact and benefits of market developments, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... LOVELAND, Colo. , Jan. 16, 2017  Northern ... , is bringing advanced laser treatments to ... specialty clinic focuses solely on the removal of unwanted ... and fading for tattoo cover-ups. "Tattoos are ... out the way we hope they would," said ...
(Date:1/16/2017)... January 16, 2017 ... Product Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl ... Beverages, Surface Coatings & Paints), Region - ... the market was valued at USD 4.51 ... reach USD 6.41 Billion by 2021, at ...
(Date:1/16/2017)... -- Transparency Market Research states that the leading ... a huge share of 43% in 2015. Apple Inc., F.Hoffmann-La ... overall market, grabbing the undivided attention of buyers with their ... strong product portfolio is expected to keep these companies in ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... Chief Executive Officer of the medical device company, effective immediately. , “This is ... “Kevin has a strong track record in medical device market development and ...
(Date:1/15/2017)... ... , ... Whole Health Supply, LLC is announcing the release of an updated version of their ... , The 2017 edition has wide jaws that will accommodate nails up to 4mm ... as diabetics. This handle is reinforced for extra strength when pressing down on dense nails ...
(Date:1/15/2017)... ... , ... Wondering where to go this Valentine's Day? Well, there is a ... romantic, lobster feast in the comfort of your own home. Lobster Gram is introducing ... be featured until February 15th, 2017. , Romantic Dinner one is Lobster Gram's ...
(Date:1/14/2017)... ... January 13, 2017 , ... ... Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type 2 ... notes that the many health and wellness benefits linked to a Mediterranean diet ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in Madrid ... expertly designed to meet the educational needs of European oncology clinicians and researchers who ... Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized by ...
Breaking Medicine News(10 mins):